Chemotherapy hypersensitivity reaction (platinum/taxane)
Infusion reactions and anaphylaxis to cytotoxic agents · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Taxanes typically cause first-dose infusion reactions within minutes (facial flushing, back pain, dyspnoea) driven by non-IgE mechanisms, whereas platinum agents cause IgE-mediated reactions after several cycles of sensitisation. Recognising the pattern directs premedication, rate adjustment, or desensitisation when the drug is essential.
Red flags
- Hypotension, wheeze or airway swelling
- Severe back/chest/pelvic pain during infusion
- Reaction recurring despite premedication
- Platinum reaction after multiple cycles (IgE sensitisation)
- Oxygen desaturation
Assessment
Differential diagnosis
- Taxane infusion reaction (first/second dose, non-IgE)
- Platinum IgE-mediated hypersensitivity (after multiple cycles)
- Cytokine-release reaction to monoclonal agents
- Vehicle reaction (Cremophor/polysorbate)
- Anxiety or vasovagal reaction
Investigations
- Document timing relative to infusion start and cycle number
- Continuous monitoring during infusion
- Mast cell tryptase after significant reactions
- Skin testing to the platinum agent to confirm IgE sensitisation
- Pre-infusion observations and symptom grading (CTCAE)
Management
- Stop the infusion immediately at the first sign of a reaction
- Assess severity: treat airway/cardiovascular compromise as anaphylaxis with IM adrenaline
- Give oxygen, IV fluids and antihistamine; add corticosteroid
- For mild taxane reactions, once settled, restart at a slower rate with enhanced premedication
- For platinum reactions, perform skin testing and plan formal desensitisation if the drug is essential
- Ensure robust premedication (corticosteroid, H1 and H2 antihistamine) before future cycles
- Involve oncology and allergy to decide between rechallenge, desensitisation or alternative agent
- Document the reaction grade and mechanism clearly in the chemotherapy record
Drugs & doses
Adrenaline IM — 500 mcg (0.5 mL 1:1000) for anaphylaxis
Chlorphenamine — 10 mg IV/IM for cutaneous/systemic reactions
Hydrocortisone — 200 mg IV for moderate-severe reactions
Dexamethasone — 20 mg IV/oral as premedication before taxanes
Ranitidine alternative H2 blocker (famotidine 20 mg IV) — as premedication adjunct
Salbutamol — 5 mg nebulised for bronchospasm
Disposition
Observe after mild reactions and continue with enhanced premedication; refer significant platinum reactions to allergy for skin testing and desensitisation planning.
Complications & pitfalls
- Anaphylaxis and cardiovascular collapse
- Interruption of essential cancer treatment
- Breakthrough reactions during desensitisation
- Progressive severity with repeated platinum exposure
- Delay to oncology regimen
Exam pearls
- Taxane reactions occur on first/second exposure and are usually rate-related; platinum reactions need prior sensitisation
- Robust corticosteroid and antihistamine premedication prevents most taxane reactions
- Skin testing predicts platinum hypersensitivity and guides desensitisation
- Desensitisation allows continued use of an essential agent in a monitored setting
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.